Aapro M S, Alberts D S, Salmon S E
Cancer Chemother Pharmacol. 1983;10(3):161-6. doi: 10.1007/BF00255753.
Purified human leukocyte interferon produced by recombinant techniques (IFN-alpha A) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents alone or in combination was tested against various human tumor cell lines, using a modified soft agar clonogenic assay. Three human tumor cell lines (myeloma, RPMI 8226; breast, MCF-7; and colon, WiDR) showed sensitivity to these agents at clinically achievable drug concentrations. Statistically significant synergistic activity against in vitro colony formation was observed with the combination of VLB and IFN-alpha A. An additive or sub-additive effect was usually observed with the other agents tested. Continuous exposure of the 8226 myeloma cell line to both IFN-alpha A and PLAT showed evidence of a more significant potentiation. It is hypothesized that the synergistic effect observed between VLB and IFN-alpha A is due to some of their common mechanisms of action.
采用重组技术生产的纯化人白细胞干扰素(IFN-αA),与化疗药物长春碱(VLB)、长春新碱(VCR)、长春地辛(VDS)、长春罗新(VZL)、顺铂(PLAT)、阿霉素(DOXO)、依托泊苷(VP-16)和美法仑(MEL)进行了体外试验。使用改良的软琼脂克隆形成试验,检测了这些药物单独或联合使用时对各种人类肿瘤细胞系的活性。三种人类肿瘤细胞系(骨髓瘤,RPMI 8226;乳腺癌,MCF-7;结肠癌,WiDR)在临床可达到的药物浓度下对这些药物敏感。观察到VLB与IFN-αA联合使用对体外集落形成具有统计学显著的协同活性。对于其他受试药物,通常观察到相加或亚相加效应。8226骨髓瘤细胞系持续暴露于IFN-αA和PLAT两者时,显示出更显著增强的证据。据推测,VLB与IFN-αA之间观察到的协同效应是由于它们的一些共同作用机制。